Cargando…
Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
Dendritic cell (DC) based cancer immunotherapy aims at the activation of the immune system, and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the tumor. DCs represent a heterogeneous cell population, including conventional DCs (cDCs), consisting of cDC1s, cDC2s, plasmacyto...
Autores principales: | Huber, Anne, Dammeijer, Floris, Aerts, Joachim G. J. V., Vroman, Heleen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287551/ https://www.ncbi.nlm.nih.gov/pubmed/30559743 http://dx.doi.org/10.3389/fimmu.2018.02804 |
Ejemplares similares
-
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
por: van Gulijk, Mandy, et al.
Publicado: (2018) -
Dendritic Cell Subsets in Asthma: Impaired Tolerance or Exaggerated Inflammation?
por: Vroman, Heleen, et al.
Publicado: (2017) -
Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014) -
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2023) -
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
por: Belderbos, Robert A., et al.
Publicado: (2019)